Janeo

Sitagliptin, the active ingredient in Janeo, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients by enhancing incretin activity, helping regulate blood glucose levels and is used as part of a comprehensive diabetes management plan.

GNH USA supplies Janeo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU Good Manufacturing Practice and provides regulatory‑compliant documentation for importers.

Sitagliptin is used in the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion. - Type 2 diabetes mellitus: improves glycemic control when added to diet, exercise and other antidiabetic agents. - Adults inadequately controlled on metformin alone: provides additional HbA1c reduction. - Patients requiring once‑daily oral therapy: offers convenient dosing with a low risk of hypoglycemia when used as monotherapy.

Sitagliptin may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea - Headache - Nasopharyngitis - Upper respiratory tract infection - Diarrhea

Serious or Rare Side Effects: - Pancreatitis - Severe allergic reactions (e.g., Stevens‑Johnson syndrome) - Joint pain - Bullous skin eruption - Severe hypoglycemia when combined with insulin or sulfonylureas - Hepatic injury

When prescribing or dispensing sitagliptin, several safety considerations should be observed. - Renal impairment: dose adjustment may be required. - Hepatic impairment: use with caution and monitor liver function. - Concomitant insulin or sulfonylureas: increased risk of hypoglycemia. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Monitor blood glucose regularly: adjust therapy based on glycemic response. - Store at room temperature: keep in the original pack, protect from moisture.

Sitagliptin can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Co‑administration with other DPP‑4 inhibitors (e.g., saxagliptin) – additive DPP‑4 inhibition. - Combination with insulin secretagogues (e.g., sulfonylureas) – heightened hypoglycemia risk. - Use with drugs known to cause pancreatitis (e.g., GLP‑1 analogues) – may exacerbate pancreatic inflammation.

Moderate Interactions (Monitor Closely): - CYP2C8 substrates (e.g., rosiglitazone) – possible increased exposure. - Diuretics (e.g., thiazides) – may affect glucose control. - Warfarin – monitor INR for potential interaction.